VolitionRX (NYSEAMERICAN:VNRX) Stock Breaks Below 50-Day Moving Average – Here’s Why

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.35 and traded as low as $0.1801. VolitionRX shares last traded at $0.1801, with a volume of 475,876 shares changing hands.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, VolitionRX presently has an average rating of “Hold” and an average price target of $28.00.

VolitionRX Stock Down 4.5%

The firm has a fifty day simple moving average of $0.35 and a 200-day simple moving average of $1.46. The company has a market cap of $2.46 million, a PE ratio of -0.05 and a beta of 1.17.

VolitionRX (NYSEAMERICAN:VNRX) last posted its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.41 million. Equities research analysts forecast that VolitionRX Limited will post -1.55 earnings per share for the current fiscal year.

About VolitionRX

VolitionRx Ltd. is a biotechnology company developing blood-based diagnostic tests designed to help detect and monitor cancer and other diseases. Its technology platform, Nu.Q, measures nucleosomes—small fragments of DNA and associated proteins released into the bloodstream during cell death—which may provide information about disease activity.

The company’s products include Nu.Q Vet, a suite of blood tests developed for veterinary oncology. The tests are intended to support cancer screening, diagnosis, and monitoring in dogs and other companion animals.